Eagle Aims To Meet Extra Vasopressin Demand Caused By Covid
Vasopressin Share Expected To Grow; ‘Unknown Is What Happens To Price’
Eagle management provided detailed insight into the existing market for vasopressin, which it entered in January with the first generic version of Endo’s Vasostrict. The US-based player believes operating cash flows for the year, boosted also by its Pemfexy (pemetrexed) launch, could top $170m, paving the way for a major acquisition.
